Search Results - "OLDENKOTT, B"

High-risk additional chromosomal abnormalities at low blast counts herald death by CML by Hehlmann, Rüdiger, Voskanyan, Astghik, Lauseker, Michael, Pfirrmann, Markus, Kalmanti, Lida, Rinaldetti, Sebastien, Kohlbrenner, Katharina, Haferlach, Claudia, Schlegelberger, Brigitte, Fabarius, Alice, Seifarth, Wolfgang, Spieß, Birgit, Wuchter, Patrick, Krause, Stefan, Kolb, Hans-Jochem, Neubauer, Andreas, Hossfeld, Dieter K., Nerl, Christoph, Gratwohl, Alois, Baerlocher, Gabriela M., Burchert, Andreas, Brümmendorf, Tim H., Hasford, Jörg, Hochhaus, Andreas, Saußele, Susanne, Baccarani, Michele

“…Blast crisis is one of the remaining challenges in chronic myeloid leukemia (CML). Whether additional chromosomal abnormalities (ACAs) enable an earlier…”
Get full text

Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML by Hehlmann, Rüdiger, Voskanyan, Astghik, Lauseker, Michael, Pfirrmann, Markus, Kalmanti, Lida, Rinaldetti, Sebastien, Kohlbrenner, Katharina, Haferlach, Claudia, Schlegelberger, Brigitte, Fabarius, Alice, Seifarth, Wolfgang, Spieß, Birgit, Wuchter, Patrick, Krause, Stefan, Kolb, Hans-Jochem, Neubauer, Andreas, Hossfeld, Dieter K., Nerl, Christoph, Gratwohl, Alois, Baerlocher, Gabriela M., Burchert, Andreas, Brümmendorf, Tim H., Hasford, Jörg, Hochhaus, Andreas, Saußele, Susanne, Baccarani, Michele

“…An amendment to this paper has been published and can be accessed via a link at the top of the paper…”
Get full text

Tolerance, safety, and kinetics of the new antineoplastic compound dexniguldipine-HCl after oral administration: a phase I dose-escalation trial by Ukena, D, Boewer, C, Oldenkott, B, Rathgeb, F, Wurst, W, Zech, K, Sybrecht, G W

“…Dexniguldipine-HCl is a new dihydropyridine compound that exerts selective antiproliferative activity in a variety of tumor models and, in addition, has a high…”
Get full text

An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia by Glasmacher, Axel, Cornely, Oliver, Ullmann, Andrew J., Wedding, Ulrich, Bodenstein, Heinrich, Wandt, Hannes, Boewer, Christian, Pasold, Rita, Wolf, Hans-Heinrich, Hänel, Mathias, Dölken, Gottfried, Junghanss, Christian, Andreesen, Reinhard, Bertz, Hartmut

“…Objectives: This trial studied the efficacy and safety of itraconazole and fluconazole in the prevention of invasive fungal infections in neutropenic patients…”
Get full text

Value of sonographic diagnosis in retroperitoneal teratoma in adults by Kämmer, J C, Oldenkott, B

“…A 56-year old man was admitted with a tumour-like lesion located in the retroperitoneal space with adherence to the left adrenal gland. An extensive diagnostic…”
Get more information

Pro and contra early systemic therapy of malignant tumors by Oldenkott, B, Boewer, C

Get more information

Tolerance, safety, and kinetics of the new antineoplastic compound dexniguldipine-HCI after oral administration : a phase I dose-escalation trial by UKENA, D, BOEWER, C, OLDENKOTT, B, RATHGEB, F, WURST, W, ZECH, K, SYBRECHT, G. W

Get full text

A phase II trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma by Kreuser, E D, Hilgenfeld, R U, Matthias, M, Hoksch, B, Boewer, C, Oldenkott, B, Lenk, H, Wiener, N, Boese-Landgraf, J, Schalhorn, A

“…Preclinical data suggest that folinic acid as well as interferon alpha-2b may enhance the antitumor activity of 5-fluorouracil (5-FU). In a phase I trial, we…”
Get more information

A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma by Kreuser, E D, Hilgenfeld, R U, Matthias, M, Hoksch, B, Boewer, C, Oldenkott, B, Knauf, W U, Boese-Landgraf, J, Schalhorn, A, Zeitz, M

“…Preclinical data suggest that both folinic acid and interferon may enhance the efficacy of 5-fluorouracil (5-FU) in colorectal carcinoma. We therefore…”
Get more information